FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Issues Sun Pharmaceutical FDA-483

[ Price : $8.95]

FDA releases an FDA-483 with six observations from an inspection at Sun Pharmaceuticals Halol, India, manufacturing facility.

FDA Proposed Rule Nixes Irradiation Regulation

[ Price : $8.95]

Federal Register proposed rule: FDA proposes to repeal a regulation that requires an FDA-approved NDA or ANDA for any drug product...

FDA Panel to Review Celltrion Rituximab Biosimilar

[ Price : $8.95]

Federal Register notice: FDA announces a 10/10 Oncologic Drugs Advisory Committee meeting to review a Celltrion BLA for a proposed...

Workshop on Evidence-based Transplant Treatment Decisions

[ Price : $8.95]

Federal Register notice: FDA announces a public workshop entitled Evidence-Based Treatment Decision in Transplantation: Patient In...

FDA Proposing Digital Health Center of Excellence

[ Price : $8.95]

FDA commissioner Scott Gottlieb and CDRH director Jeffrey Shuren propose a digital health Center of Excellence.

Liva Pharmaceuticals FDA-483

[ Price : $8.95]

FDA releases the FDA-483 with five observations from an inspection at Indias Live Pharmaceuticals.

Praluent sBLA Accepted for Reduced MACE Labeling

[ Price : $8.95]

FDA accepts for review a Sanofi and Regeneron Pharmaceuticals supplemental BLA for Praluent (alirocumab) to update the Prescribing...

Orphan Status for Syntimmune Pemphigus Therapy

[ Price : $8.95]

FDA grants Syntimmune an orphan drug designation for SYNT001 for treating pemphigus.

Merck sBLA for Keytruda in Lung Cancer

[ Price : $8.95]

FDA accepts for priority review a supplemental BLA for Keytruda, an anti-PD-1 therapy, as monotherapy for first-line treatment of ...

ANDA Clinical Study Dataset Guidance

[ Price : $8.95]

FDA publishes a guidance recommending technical specifications and general considerations for submitting certain ANDA comparative ...